<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640818</url>
  </required_header>
  <id_info>
    <org_study_id>EOCNSIMS.2001</org_study_id>
    <nct_id>NCT04640818</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy</brief_title>
  <official_title>Safety and Efficacy of a Therapy With Cladribine Following a Treatment With Anti CD20 Compounds in Relapsing Multiple Sclerosis Patients: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Claudio Gobbi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck AG Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale Civico, Lugano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolonged anti CD20 therapy for the treatment of active multiple sclerosis leading to&#xD;
      continuous B cell depletion is associated with hypogammaglobulinemia predisposing to a&#xD;
      potentially increased risk of serious infections, particularly in the more disabled and aged&#xD;
      patients. No data have been published on the sequential use of anti CD20 therapies and&#xD;
      cladribine, that is thought to act as an immune reconstitution agent. his study aims at&#xD;
      investigating IgG and IgM serum concentration changes at 6 and 12 months after switching to&#xD;
      cladribine in patients previously treated with anti CD20 therapies (ie, ocrelizumab ≥1.8 gr&#xD;
      or rituximab 3.0 gr) for ≥18 months, as compared to continued anti CD20 therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will include patients with remitting relapsing multiple sclerosis&#xD;
      consulting the Multiple Sclerosis Center of Neurocenter of Southern Switzerland.&#xD;
&#xD;
      Enrolled patients will have 5 Study Visits, one every 3 months according to clinical&#xD;
      practice. At visits at 3 and 6 months only adverse events will be collected for study&#xD;
      purposes. Clinical assessments will be performed at baseline, Month 6 and Month 12. Clinical&#xD;
      assessments correspond to medical exams performed routinely in MS patients treated with anti&#xD;
      CD20 or cladribine therapy: clinical assessments, monitoring haemoglobin parameters, serum&#xD;
      immunoglobulins, liver and renal function.(6, 12 months), radiological disability progression&#xD;
      and biomarker of ongoing neurodegeneration (12 months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in IgG serum concentrations in Cald-Group</measure>
    <time_frame>6 months</time_frame>
    <description>Standard laboratory test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in IgM serum concentrations in Cald-Group</measure>
    <time_frame>6 months</time_frame>
    <description>Standard laboratory test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in IgG serum concentrations in Clad-Group</measure>
    <time_frame>12 months</time_frame>
    <description>Standard laboratory test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in IgM serum concentrations in Clad-Group</measure>
    <time_frame>12 months</time_frame>
    <description>Standard laboratory test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in IgG serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies</measure>
    <time_frame>6 months</time_frame>
    <description>Standard laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IgM serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies</measure>
    <time_frame>6 months</time_frame>
    <description>Standard laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IgG serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies</measure>
    <time_frame>12 months</time_frame>
    <description>Standard laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IgM serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies</measure>
    <time_frame>12 months</time_frame>
    <description>Standard laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching NEDA -3</measure>
    <time_frame>12 months</time_frame>
    <description>NEDA -3: no relapses, no disability progression, no new/enlarging or Gd enhancing brain or spinal MR lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate (ARR) over 12 months after switching to cladribine as compared to patients continuing anti CD20 therapies</measure>
    <time_frame>12 months</time_frame>
    <description>ARR will be calculated based on recorded number of relapses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with disability progression</measure>
    <time_frame>6 months</time_frame>
    <description>Expanded disability scale 0-6 (6 worst outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with disability progression</measure>
    <time_frame>12 months</time_frame>
    <description>Expanded disability scale 0-6 (6 worst outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/volume of cumulative new T2/ enlarging lesions at brain and spinal MRI over 12 months after switching to cladribine, as compared to patients continuing anti CD20 therapies</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/volume of cumulative Gd enhancing lesions at brain and spinal MRI over 12 months after switching to cladribine, as compared to patients continuing anti CD20 therapies</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum neurofilament light chain concentration</measure>
    <time_frame>12 months</time_frame>
    <description>single-molecule array (Simoa) assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of infections</measure>
    <time_frame>6 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of infections</measure>
    <time_frame>12 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensity of infections</measure>
    <time_frame>6 months</time_frame>
    <description>Safety endpoint, intensity will be rated according to the following definitions:&#xD;
Mild: Awareness of a sign or symptom that does not interfere with the study participant's usual activity or is transient, resolved without treatment and with no sequelae; Moderate: Interferes with the study participant's usual activity and/or requires symptomatic treatment; Severe: Symptom(s) causing severe discomfort and significant impact of the study participant's usual activity and requires treatment.&#xD;
Serious: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, or is otherwise considered as medically important.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensity of infections</measure>
    <time_frame>12 months</time_frame>
    <description>Safety endpoint, intensity will be rated according to the following definitions:&#xD;
Mild: Awareness of a sign or symptom that does not interfere with the study participant's usual activity or is transient, resolved without treatment and with no sequelae; Moderate: Interferes with the study participant's usual activity and/or requires symptomatic treatment; Severe: Symptom(s) causing severe discomfort and significant impact of the study participant's usual activity and requires treatment.&#xD;
Serious: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, or is otherwise considered as medically important.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with abnormal creatinine values of clinical relevance</measure>
    <time_frame>6 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with abnormal creatinine values of clinical relevance</measure>
    <time_frame>12 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with abnormal ASAT values of clinical relevance</measure>
    <time_frame>6 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with abnormal ASAT values of clinical relevance</measure>
    <time_frame>12 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with abnormal ALAT values of clinical relevance</measure>
    <time_frame>6 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with abnormal ALAT values of clinical relevance</measure>
    <time_frame>12 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with any abnormal hematology values of clinical relevance</measure>
    <time_frame>6 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with any abnormal hematology values of clinical relevance</measure>
    <time_frame>12 months</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>CLAD-GROUP</arm_group_label>
    <description>Patients with cladribine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD20-GROUP</arm_group_label>
    <description>Patients with anti CD20 therapy (ocrelizumab or rituximab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine Oral Tablet</intervention_name>
    <description>Treatment according to the label and medical prescription</description>
    <arm_group_label>CLAD-GROUP</arm_group_label>
    <other_name>Mavenclade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Treatment according to the label and medical prescription</description>
    <arm_group_label>CD20-GROUP</arm_group_label>
    <other_name>Mabthera, Rixathon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocrelizumab</intervention_name>
    <description>Treatment according to the label and medical prescription</description>
    <arm_group_label>CD20-GROUP</arm_group_label>
    <other_name>Ocrevus</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapsing multiple sclerosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsing MS according to Lublin;&#xD;
&#xD;
          -  Treatment with ocrelizumab or rituximab for ≥18 months and having received 1.8 / 3.0&#xD;
             gr, respectively;&#xD;
&#xD;
          -  CLAD_GROUP: Planning to switch to cladribine because of concerns about increased risks&#xD;
             of infections related to hypogammaglobulinemia developing during long term anti CD20&#xD;
             therapies or a documented decrease of ≥10% IgG and/or IgM compared to pre- anti CD20&#xD;
             therapy;&#xD;
&#xD;
          -  or CD20_GROUP: no need to stop CD20 therapy due decrease of ≥10% IgG and/or IgM, or&#xD;
             increased risk of infections related to hypogammaglobulinemia or other reasons,&#xD;
             continued anti CD20 therapies clinically indicated;&#xD;
&#xD;
          -  EDSS ≤7.0;&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non relapsing MS;&#xD;
&#xD;
          -  Pregnancy - breastfeeding;&#xD;
&#xD;
          -  Contraindications to perform MRI;&#xD;
&#xD;
          -  Contraindication to receive cladribine or to continue anti CD therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Gobbi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Regionale di Lugano, Neurocentro della Svizzera italiana, Centro Sclerosi multipla</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudio Gobbi, MD</last_name>
    <phone>+41 91 811 6921</phone>
    <email>claudio.gobbi@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chiara Zecca, MD</last_name>
    <phone>+41 91 811 6921</phone>
    <email>chiara.zecca@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Gobbi, Dr med.</last_name>
      <phone>+41 811 91 6479</phone>
      <email>claudio.gobbi@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Chiara Zecca, Dr med.</last_name>
      <phone>+41 811 91 6604</phone>
      <email>chiara.zecca@eoc.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Civico, Lugano</investigator_affiliation>
    <investigator_full_name>Claudio Gobbi</investigator_full_name>
    <investigator_title>Head Physician</investigator_title>
  </responsible_party>
  <keyword>anti CD20 therapy</keyword>
  <keyword>cladribine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

